Brii Biosciences Past Earnings Performance
Past criteria checks 0/6
Brii Biosciences has been growing earnings at an average annual rate of 21.5%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 79.9% per year.
Key information
21.5%
Earnings growth rate
47.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 79.9% |
| Return on equity | -10.4% |
| Net Margin | -242.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Brii Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 134 | -327 | 189 | 384 |
| 31 Mar 23 | 128 | -405 | 192 | 412 |
| 31 Dec 22 | 122 | -484 | 195 | 441 |
| 30 Sep 22 | 99 | -1,021 | 223 | 518 |
| 30 Jun 22 | 75 | -1,558 | 251 | 595 |
| 31 Mar 22 | 84 | -2,861 | 230 | 545 |
| 31 Dec 21 | 93 | -4,164 | 208 | 495 |
| 30 Sep 21 | 100 | -3,999 | 169 | 631 |
| 30 Jun 21 | 107 | -3,835 | 130 | 768 |
| 31 Mar 21 | 94 | -2,512 | 117 | 822 |
| 31 Dec 20 | 82 | -1,190 | 103 | 876 |
| 31 Dec 19 | 20 | -521 | 63 | 84 |
Quality Earnings: 2137 is currently unprofitable.
Growing Profit Margin: 2137 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2137 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare 2137's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2137 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 2137 has a negative Return on Equity (-10.4%), as it is currently unprofitable.